reports
- Emira Sagaama
- Rok Stibric
- Emira Sagaama
- Rok Stibric
- Martial Descoutures
- Martial Descoutures
Novartis announces plans to build flagship manufacturing hub in North ...
Novartis announces plans to build flagship manufacturing hub in North Carolina Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic areas in one geographic locationMarks latest milestone in company’s previously announced $23 billion investment in US infrastructure East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufa...
Evotec SE: 2 directors
Two Directors at Evotec SE sold/bought 36,000 shares at between 5.156EUR and 5.160EUR. The significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
AstraZeneca: 1 director
A director at AstraZeneca sold 7,500 shares at 177.269USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CH...
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes (T1D), compared to placebo, in adults and children with stage 2 T1DIf approved, Teizeild would become the first disease-modifying T1D therapy in the EU Paris, November 14, 2025. The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human ...
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approb...
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 La recommandation s’appuie sur l’étude TN-10, qui démontre la capacité du Teizeild à retarder l’apparition du stade 3 du diabète de type 1 (DT1), par rapport au placebo, chez les adultes et les enfants atteints de DT1 de stad...
Sanofi: 1 director
A director at Sanofi bought 207 shares at 7,909p and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
Sanofi: Information concerning the total number of voting rights and s...
Sanofi: Information concerning the total number of voting rights and shares – October 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry u...
Sanofi: Informations relatives au nombre de droits de vote et d'action...
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Octobre 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 eurosSiège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris acti...
Novartis opens new radioligand therapy manufacturing facility in Calif...
Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan Carlsbad location is company’s third US-based radioligand therapy (RLT) manufacturing site New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and HawaiiFirst to have delivered at scale, Novartis fortifies leadership in RLT innovation and infrastructure with California facility, additional plans for Florida and Texas Basel, November 10, 2025 – Novartis, a leading global innovative m...
Novartis AG: 1 director
A director at Novartis AG sold 20,000 shares at 101.718CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Thomas J. Schiessle
Schwache Konjunktur verzögert weiterhin „Profitability Restart“ - Mone...
Q3/25-KPIs zeigen eine Umsatz- und EBITDA Margen-Verschlechterung (Umsatz -11% YoY auf € 164 Mio./Marge: -9,17 %; EPS € -0,24), doch sind diese durch Phasing-Effekte und Reset-Einsparungen überzeichnet. Die anhaltend schwache Nachfrage im Markt für frühe Arzneimittelforschung (D&PD) konnte das gut gelaufene Geschäft von Just-Evotec Biologics (JEB) nur teilweise ausgleichen. Zudem kämpft Evotec mit Unterauslastung. Hinzu kommen Kosten im Zusammenhang mit dem Anlaufen der JEB-Anlage im französisch...
- Thomas J. Schiessle
Weak economic conditions continue to delay the 'Profitability Restart'...
Q3/25 KPIs show a decline in revenue and EBITDA margins (revenue -11% YoY to €164m / margin: -9.17%; EPS € -0.24), but these are exaggerated due to phasing effects and reset savings. The persistently weak demand in the early drug discovery (D&PD) market could only partially offset the well-performing business of Just-Evotec Biologics (JEB). Additionally, Evotec is struggling with underutilization. There are also costs associated with the start-up of the JEB facility in Toulouse, France, which is...
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study m...
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients a...
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi...
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique... ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique ; la demande supplémentaire de licence de mise sur le marché (sBLA) a été acceptée pour examen prioritaire par la FDA Les données de phase 3 qui v...
- Emira Sagaama
- Julian Dobrovolschi
- Marc Lavaud
V1S ARKEMA
LRC LEGRAND
ENX EURONEXT NV
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
UBSN UBS GROUP AG
MT ARCELORMITTAL SA
CBK COMMERZBANK AG
RHM RHEINMETALL AG
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
HOT HOCHTIEF AG
FRE FRESENIUS SE & CO. KGAA
HEN3 HENKEL AG & CO. KGAA PREF
ANA ACCIONA SA
RAA RATIONAL AG
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
OTP OTP BANK NYRT
AUTO AUTO TRADER GROUP PLC
CLNX CELLNEX TELECOM S.A.
AZN ASTRAZENECA PLC
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
PIRC PIRELLI & C. S.P.A.
DNP DINO POLSKA S.A.
MRNA MODERNA INC.
NLBR NOVA LJUBLJANSKA BANKA DD LJUBLJANA
HAG HENSOLDT AG
INPST INPOST S.A.
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
DTG DAIMLER TRUCK
UN0 UNIPER SE
- Emira Sagaama
- Julian Dobrovolschi
- Marc Lavaud
V1S ARKEMA
LRC LEGRAND
ENX EURONEXT NV
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
UBSN UBS GROUP AG
MT ARCELORMITTAL SA
DGE DIAGEO PLC
CBK COMMERZBANK AG
RHM RHEINMETALL AG
IAG INTERNATIONAL CONSOLIDATED AIRLINES GROUP SA
HOT HOCHTIEF AG
FRE FRESENIUS SE & CO. KGAA
HEN3 HENKEL AG & CO. KGAA PREF
ANA ACCIONA SA
RAA RATIONAL AG
EDW EDP RENOVAVEIS SA
AMS AMADEUS IT GROUP SA CLASS A
OTP OTP BANK NYRT
AUTO AUTO TRADER GROUP PLC
CLNX CELLNEX TELECOM S.A.
AZN ASTRAZENECA PLC
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
PIRC PIRELLI & C. S.P.A.
MRNA MODERNA INC.
NLBR NOVA LJUBLJANSKA BANKA DD LJUBLJANA
HAG HENSOLDT AG
INPST INPOST S.A.
ANE CORPORACION ACCIONA ENERGIAS RENOVABLES SA
DTG DAIMLER TRUCK
UN0 UNIPER SE
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.